Literature DB >> 26482684

Periarticular Injection After Total Knee Arthroplasty Using Liposomal Bupivacaine vs a Modified Ranawat Suspension: A Prospective, Randomized Study.

Philip N Collis1, Allison M Hunter1, Michael D Derek Vaughn1, Leah Y Carreon2, Jiapeng Huang3, Arthur L Malkani4.   

Abstract

BACKGROUND: The purpose of this study is to compare liposomal bupivacaine to a modified (Ranawat) local injection for total knee arthroplasty (TKA).
METHODS: This is a prospective, randomized study of 105 consecutive patients undergoing primary TKA. Group A patients received a periarticular injection with liposomal bupivacaine and group B with a mixture of ropivacaine, epinephrine, ketorolac, and clonidine. There were 54 patients in the group A (liposomal bupivacaine) and 51 in group B.
RESULTS: There were no differences in the groups with respect to age, sex, and preoperative knee scores. There were no differences with respect to postoperative narcotic usage and knee range of motion.
CONCLUSION: Liposomal bupivacaine as a periarticular injection after TKA demonstrated similar pain levels, narcotic usage, and range of motion compared to a modified Ranawat suspension but improved walking distance.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TKA; liposomal bupivacaine; postop pain; ranawat suspension

Mesh:

Substances:

Year:  2015        PMID: 26482684     DOI: 10.1016/j.arth.2015.09.025

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  9 in total

Review 1.  Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain.

Authors:  Thomas W Hamilton; Vassilis Athanassoglou; Stephen Mellon; Louise H Strickland; Marialena Trivella; David Murray; Hemant G Pandit
Journal:  Cochrane Database Syst Rev       Date:  2017-02-01

2.  Postoperative Pain Management With Liposomal Bupivacaine in Patients Undergoing Orthopedic Knee and Hip Arthroplasty at a Community Hospital.

Authors:  Bobby C Jacob; Samuel K Peasah; Angela O Shogbon; Ellen R Perlow
Journal:  Hosp Pharm       Date:  2017-05-01

3.  CORR Insights®: No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA.

Authors:  Philippe Richebé; Véronique Brulotte
Journal:  Clin Orthop Relat Res       Date:  2016-07-21       Impact factor: 4.176

4.  Liposomal bupivacaine in posterior spine surgery: A piece of the puzzle for postoperative pain.

Authors:  D Alex Forrester; Harrison Miner; Cameron Shirazi; Niranjan Kavadi
Journal:  J Orthop       Date:  2022-07-12

5.  Periarticular injection and continuous femoral nerve block versus continuous femoral nerve block alone on postoperative opioid consumption and pain control following total knee arthroplasty: Randomized controlled trial.

Authors:  Dennis Dimaculangan; Jin F Chen; Robert B Borzio; Julio J Jauregui; Vijay J Rasquinha; Aditya V Maheshwari
Journal:  J Clin Orthop Trauma       Date:  2017-09-21

6.  Cost-effective peri-operative pain management: assuring a happy patient after total knee arthroplasty.

Authors:  K Kim; A Elbuluk; S Yu; R Iorio
Journal:  Bone Joint J       Date:  2018-01       Impact factor: 5.082

7.  The efficacy of local liposomal bupivacaine infiltration on pain and recovery after Total Joint Arthroplasty: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Baocheng Zhao; Xinlong Ma; Jinli Zhang; Jianxiong Ma; Qing Cao
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

8.  Improved pain control with adductor canal block using liposomal bupivacaine after total knee replacement: a retrospective cohort study.

Authors:  Akshay Lakra; Matthew Grosso; Emma L Jennings; H John Cooper; Roshan P Shah; Jeffrey A Geller
Journal:  Arthroplast Today       Date:  2019-06-03

9.  Liposome bupivacaine for pain control after total knee arthroplasty: a meta-analysis.

Authors:  Zhong Qing Wu; Ji Kang Min; Dan Wang; Yong Jian Yuan; Heng Li
Journal:  J Orthop Surg Res       Date:  2016-07-22       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.